CyberLiver®

Liver disease is a global issue, the prevalence of which is staggering. It is estimated that more than 800 million people worldwide suffer from chronic liver disease and this figure is likely to grow given the ubiquity of alcohol use and obesity.

End-stage liver disease – decompensated cirrhosis – carries with it a high human and healthcare cost.

CyberLiver® is developing Prescription Digital Therapeutics aimed at halting or reversing the progression of the disease towards this stage, as well as providing effective means of managing the very ill cohort of patients already at this stage.